SEC Form 4 · accession 0001140361-15-027199
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jean Jacques Bienaime
Officer — Chief Executive Officer · Director
Period of report
Jul 7, 2015
Accepted (ET)
Jul 9, 2015 · 5:06 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 7, 2015 | S | 1,500 | $139.0664 | D | 30,258 | I | Shares held by Bienaime Family Trust |
| Common Stock | holding | — | — | — | 228,754 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price in column 4 is an average weighted price. The price actually received ranged from $137.76 to $140.50. The issuing person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.